These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38184999)

  • 1. Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH.
    Fernández-Ginés R; Encinar JA; Escoll M; Carnicero-Senabre D; Jiménez-Villegas J; García-Yagüe ÁJ; González-Rodríguez Á; Garcia-Martinez I; Valverde ÁM; Rojo AI; Cuadrado A
    Redox Biol; 2024 Feb; 69():103027. PubMed ID: 38184999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
    Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
    Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter β-TrCP delivers anti-inflammatory responses in mouse liver.
    Fernández-Ginés R; Encinar JA; Hayes JD; Oliva B; Rodríguez-Franco MI; Rojo AI; Cuadrado A
    Redox Biol; 2022 Sep; 55():102396. PubMed ID: 35839629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
    J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
    Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
    Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glycogen synthase kinase-3 enhances NRF2 protein stability, nuclear localisation and target gene transcription in pancreatic beta cells.
    Patibandla C; van Aalten L; Dinkova-Kostova AT; Honda T; Cuadrado A; Fernández-Ginés R; McNeilly AD; Hayes JD; Cantley J; Sutherland C
    Redox Biol; 2024 May; 71():103117. PubMed ID: 38479223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
    Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
    Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
    Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
    Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of NRF2 is correlated with the magnitude of inflammation and fibrosis in chronic liver disease.
    To K; Okada K; Watahiki T; Suzuki H; Tsuchiya K; Tokushige K; Yamamoto M; Ariizumi SI; Shoda J
    Cancer Med; 2023 Oct; 12(19):19423-19437. PubMed ID: 37732511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress.
    Zhang MH; Li J; Zhu XY; Zhang YQ; Ye ST; Leng YR; Yang T; Zhang H; Kong LY
    Free Radic Biol Med; 2021 Feb; 164():1-12. PubMed ID: 33388433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of scutellaria-coptis herb couple against non-alcoholic steatohepatitis via activating NRF2 and FXR pathways in vivo and in vitro.
    Xue Y; Wei Y; Cao L; Shi M; Sheng J; Xiao Q; Cheng Z; Luo T; Jiao Q; Wu A; Chen C; Zhong L; Zhang C
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116933. PubMed ID: 37482263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
    Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
    Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity.
    Han Y; Luo L; Li H; Zhang L; Yan Y; Fang M; Yu J; Gao X; Liu Y; Huang C; Fan S
    Biofactors; 2023; 49(6):1189-1204. PubMed ID: 37401768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice.
    Seedorf K; Weber C; Vinson C; Berger S; Vuillard LM; Kiss A; Creusot S; Broux O; Geant A; Ilic C; Lemaitre K; Richard J; Hammoutene A; Mahieux J; Martiny V; Durand D; Melchiore F; Nyerges M; Paradis V; Provost N; Duvivier V; Delerive P
    JHEP Rep; 2023 Apr; 5(4):100651. PubMed ID: 36866391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoplastic propels diet-induced NAFL to NASH via ER-mitochondrial tether-controlled redox switch.
    Wei J; Liu J; Wang H; Wen K; Ni X; Lin Y; Huang J; You X; Lei Z; Li J; Shen H; Lin Y
    J Hazard Mater; 2024 Mar; 465():133142. PubMed ID: 38061129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Nrf2-ARE pathway in hepatocytes protects against steatosis in nutritionally induced non-alcoholic steatohepatitis in mice.
    Lee LY; Köhler UA; Zhang L; Roenneburg D; Werner S; Johnson JA; Foley DP
    Toxicol Sci; 2014 Dec; 142(2):361-74. PubMed ID: 25294219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity.
    Park JS; Lee YS; Lee DH; Bae SH
    Free Radic Biol Med; 2019 Jun; 137():143-157. PubMed ID: 31035006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
    Song MK; Lee JH; Ryoo IG; Lee SH; Ku SK; Kwak MK
    Free Radic Biol Med; 2019 Jul; 138():33-42. PubMed ID: 31059771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoids from Scutellaria amoena C. H. Wright alleviate mitochondrial dysfunction and regulate oxidative stress via Keap1/Nrf2/HO-1 axis in rats with high-fat diet-induced nonalcoholic steatohepatitis.
    Fang QL; Qiao X; Yin XQ; Zeng YC; Du CH; Xue YM; Zhao XJ; Hu CY; Huang F; Lin YP
    Biomed Pharmacother; 2023 Feb; 158():114160. PubMed ID: 36571996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease.
    Liu P; Anandhan A; Chen J; Shakya A; Dodson M; Ooi A; Chapman E; White E; Garcia JG; Zhang DD
    Redox Biol; 2023 Feb; 59():102570. PubMed ID: 36495698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.